跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 149 条关于
“loncastuximab tesirine-Ipyl”
全部
149
临床试验
101
药物
20
机构
1
资讯
27
去年
ADC Therapeutics' Zynlonta Faces Competition, Poised for Potential Second-Line DLBCL Approval
去年
Loncastuximab Tesirine Shows Promise in Treating HLH Associated with DLBCL
去年
Loncastuximab Tesirine Shows High Efficacy in Treating High-Risk Lymphoma Types
去年
Loncastuximab Tesirine Shows Promise in Relapsed/Refractory Follicular and Marginal Zone Lymphomas
3年前
Initial Safety Run-In Results of the Phase 3 LOTIS-5 Trial for R/R DLBCL Treatment
去年
Novel Combination Therapy Shows Promise in Diffuse Large B-Cell Lymphoma Treatment
去年
ZYNLONTA® Plus Rituximab Demonstrates High Response Rates in Relapsed/Refractory Follicular Lymphoma
4个月前
UC Davis Tests Novel Immunotherapy-Chemotherapy Sequence for High-Risk Diffuse Large B-Cell Lymphoma
去年
Managing Adverse Events in DLBCL Targeted Therapies: Key Considerations for Clinicians
去年
ADC Therapeutics Announces Data Update from LOTIS-7 Trial of ZYNLONTA® Plus Glofitamab in R/R DLBCL
第 1 页,共 3 页
上一页
下一页